These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29251661)

  • 21. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
    Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
    Hill-McManus D; Soto E; Marshall S; Lane S; Hughes D
    Br J Clin Pharmacol; 2018 Jan; 84(1):142-152. PubMed ID: 28888218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of available urate-lowering drugs: a critical review.
    Strilchuk L; Fogacci F; Cicero AF
    Expert Opin Drug Saf; 2019 Apr; 18(4):261-271. PubMed ID: 30915866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination urate-lowering therapy in the treatment of gout: What is the evidence?
    Perez-Ruiz F; Dalbeth N
    Semin Arthritis Rheum; 2019 Feb; 48(4):658-668. PubMed ID: 30075988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2019 Jul; 57(7):345-352. PubMed ID: 30990408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    Pui K; Gow PJ; Dalbeth N
    J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing Gout Flares in the Elderly: Practical Considerations.
    Abhishek A
    Drugs Aging; 2017 Dec; 34(12):873-880. PubMed ID: 29214511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
    Pérez-Ruiz F; Jansen T; Tausche AK; Juárez-Campo M; Gurunath RK; Richette P
    Drugs Context; 2019; 8():212581. PubMed ID: 31191704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.
    Poiley J; Steinberg AS; Choi YJ; Davis CS; Martin RL; McWherter CA; Boudes PF;
    Arthritis Rheumatol; 2016 Aug; 68(8):2027-34. PubMed ID: 26989892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
    Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Challenges of Approaching and Managing Gout.
    Fields TR
    Rheum Dis Clin North Am; 2019 Feb; 45(1):145-157. PubMed ID: 30447743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.